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Numerous evidences from prevention studies in humans, support the existence of an association between green tea polyphenols
consumption and a reduced cancer risk. Prostate cancer is one of the most frequently diagnosed male neoplasia in the Western
countries, which is in agreement with this gland being particularly vulnerable to oxidative stress processes, often associated with
tumorigenesis. Tea polyphenols have been extensively studied in cell culture and animal models where they inhibited tumor onset
and progression. Prostate cancer appears a suitable target for primary prevention care, since it grows slowly, before symptoms
arise, thus oﬀering a relatively long time period for therapeutic interventions. It is, in fact, usually diagnosed in men 50-year-old
or older, when even a modest delay in progression of the disease could significantly improve the patients quality of life. Although
epidemiological studies have not yet yielded conclusive results on the chemopreventive and anticancer eﬀect of tea polyphenols,
there is an increasing trend to employ these substances as conservative management for patients diagnosed with less advanced
prostate cancer. Here, we intend to review the most recent observations relating tea polyphenols to human prostate cancer risk, in
an attempt to outline better their potential employment for preventing prostate cancer.
1. Introduction
In the past decade, prostate cancer (PCa) has been one of the
most frequently diagnosed male neoplasias in the Western
countries, and despite recent important progress, it contin-
ues to represent a major cause of cancer-related mortality.
The reasons of this high incidence are unknown. Racial and
ethnic diﬀerences in PCa incidence and mortality are well
known, with African-American men being at the greatest
risk for diagnosis, followed by Caucasian and Hispanic men.
Asian-Americans seem to be at the lowest risk for PCa [1].
Generally, PCa appears to be sporadically inherited (less
than 10%). These observations highlight the hypothesis that
interactions between multiple genetic and ambient factors
are significative determinant in PCa development.
Diet is believed one of the most probable and deter-
minant environmental risk factors. The hypothesis results
were strengthened by ecological studies showing that the PCa
incidence rapidly increases in Asian immigrants that have
assimilated Western diet and way of living, and in Asian men
that, although living in their original countries, are contami-
nated by Western lifestyle, tending to substitute soy, tea, fish,
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fruits, and vegetables consumption with red meat and fatty
food [2]. The molecular mechanisms, through which racial,
genetic, environmental conditions aﬀect PCa development,
are still a matter of discussion.
Numerous experimental evidences suggest that both
dietary and lifestyle factors act by promoting chronic inflam-
mation and/or oxidative stress leading to DNA damage,
epigenetic modifications, or other alterations associated with
cancer initiation. Altogether, the experimental data so far
produced suggest that antioxidant and anti-inflammatory
agents may play a promising role for PCa prevention [3].
In fact, (1) the proliferative inflammatory atrophy (PIA)
has been proposed as a precursor to prostatic intraepithelial
neoplasia (PIN) that merges with high-grade PIN (HGPIN)
in about 34% of cancerous lesions [4]. Chronic inflammation
may damage epithelial cells and lead to proliferative lesions,
likely PIN lesions, and prostatic carcinomas precursors [5];
(2) several evidences have suggested that oxidative stress,
following from the imbalance of reactive oxygen species
(ROS) production and cellular antioxidant defences, is one
of the most critical aging-associated factor on prostate car-
cinogenesis. Cumulative ROS eﬀect possibly results in lipids,
proteins, andDNA damage [6]. Prostate gland is known to be
particularly vulnerable to oxidative stress, probably because
of inflammation and hormonal deregulation processes and
epigenetic modifications, frequently occurring in the organ.
It is worth to underline that PCa is a suitable target for
primary chemopreventive interventions, since it is a unique
malignancy that generally grows very slowly, before symp-
toms arise. As a consequence, it oﬀers a relatively long time
period for therapeutic interventions and, because of its long
latency, it is typically diagnosed in 50-year-old men or older,
when even a modest delay in the disease progression could
significantly improve the patient quality of life.
Considering that most of the known chemotherapeutic
treatments against PCa carry side eﬀects risk, there is an
increasing trend to employ conservative management for
patients diagnosed with less advanced PCa, that may not
require treatment. These types of tumors, in fact, are rela-
tively indolent, almost never relapse after local therapy, and
probably require a simple watchful waiting.
In order to obtain new additional opportunities improv-
ing nontoxic chemopreventive strategies, dietary substances
consumption, especially tea polyphenols, can represent an
important clinical challenge.
Tea, the most popular worldwide consumed beverage
after water, obtained from the dried leaves of the plant
Camellia sinensis, has been studied extensively for its eﬀects
on cancer prevention. The major polyphenols in green tea,
generally known as catechins, (-)-epigallocatechin-3-gallate
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-
gallate (ECG), and (-)-epicatechin (EC), display meta-5,7-
dihydroxyl groups on the A ring [7] and di- or trihydroxyl
groups on the B ring, that represent the principal site of
antioxidant reactions [8]. EGCG and ECG, harboring D ring
(gallate), present maximal antioxidant activity (Figure 1).
The above characteristics allow tea polyphenols to react with
ROS (superoxide radical, singlet oxygen, hydroxyl/peroxyl
radical, peroxynitrite) [9] and prevent, as strong metal ion
chelators, ROS output following several compounds auto-
oxidation. Due to the ability of acting as good donors for
hydrogen bonding, an accurate prediction about tea poly-
phenols solubility and permeability remains, at the moment,
an elusive target [10].
Tea polyphenols have been shown to inhibit tumori-
genesis and tumor progression, at diﬀerent organ sites,
in diﬀerent animal models for human cancer. Many evi-
dences highlighted that these compounds aﬀect enzyme
activities and signal transduction pathways, resulting in cell
proliferation suppression, apoptosis enhancement, as well as
angiogenesis and cell invasion inhibition, finally inhibiting
the development of the disease.
To date, an association between green tea polyphenols
consumption and reduced cancer risk is also supported by
human cancer prevention studies, although epidemiological
evidences have not yet yielded conclusive results on their
chemopreventive and anticancer eﬀect against PCa, possibly
owing to diﬀerent confounding factors [11].
2. Mechanisms of GTCs Action in PCa Cell Lines
Several mechanisms involved in GTCs inhibition of cancer
formation/progression are recently reviewed by numerous
Authors [12–15]. Certainly, GTCs, through their antioxidant
activity, are able to quench ROS and chelate transition met-
als, produced during all the carcinogenesis stage. However,
it has been reported that also GTCs can be a source of
ROS generation, inducing oxidative stress and consequently
activating apoptotic pathways [16].
GTCs, and especially EGCG, are capable of modulating
a plethora of cell signalling pathways crucial for cancer
cells transformation and survival, including, but not limited
to, the mitogen-activated protein kinase (MAP-kinase), the
nuclear factor-kappa B (NFκB), and the insulin-like growth
factor (IGF)/IGF-1 receptor pathways.
With regard to the prostate-specific processes GTCs are
able to aﬀect androgen receptor (AR) downregulation and
prostate-specific antigen (PSA) expression [14, 17].
Here below, we report the most probable GTCs mecha-
nisms of action in some PCa cell lines.
2.1. Inhibition of Cell Proliferation and Cell Cycle Arrest.
GTCs exhibit ant-proliferative eﬀects versus both androgen-
sensitive and androgen-insensitive human PCa cells. The
eﬀect is mediated by cell cycle deregulation and cell death
induction [18].
We showed that GTCs action is cancer specific, since
GTCs is capable of inducing growth arrest both in SV-
40 immortalized prostate epithelial cells (PNT1a) and in
tumorigenic androgen-independent PCa cells (PC3), while
normal human prostate epithelial cells were not significantly
aﬀected, even when EGCG was administered at higher doses
[19]. The IC50 of EGCG ranges from about 40 to about
200 μM, depending on the cell line type (LNCap < PNT1a
< DU145 < PC3), as well as the length of the experiment,
ranging from 24 to 72 hours [18, 20]. Our results were
confirmed by other authors in normal fibroblasts [20, 21].
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Figure 1: Chemical structure of the green tea catechins obtained from the dried leaves of the plant Camellia sinensis.
Both in LnCap and DU145 cells, EGCG treatment resulted in
the cell cycle arrest at G0/G1 phase (dose dependent) and the
cyclin kinase inhibitor WAF1/p21 and apoptosis induction,
irrespective of the AR presence or p53 cell status. Cells
harbouring an active p53 protein respond to lower EGCG
doses than cells with a mutated p53 [18].
It was shown that EGCG treatment of LNCaP andDU145
cells causes an induction of G1-phase cyclin kinase inhibitors,
that, in turn, inhibit the cyclin-cycline-dependent kinase
(CDK) complexes operative in the G0/G1 phase, thereby
causing a cell cycle arrest, a possible irreversible process
ultimately leading to apoptotic cell death [22].
2.2. Apoptosis. Hastak et al. [23] reported that EGCG induces
apoptosis in LNCaP cells mainly through modulation of
two related pathways: (i) p53 stabilization by specific phos-
phorylation and downregulation of murine double minute
2 protein (MDM2), mediated by the tumor suppressor
p14ARF; (ii) negative regulation of NFκB activity, which
results in reduction of the proapoptotic Bcl2 family protein
expression. EGCG-induced p53 stabilization causes up-
regulation of its downstream targets WAF1/p21 and Bax;
consequently, EGCG produces a change in the Bax/Bcl2 ratio,
shifting the balance between pro-/antiapoptotic proteins in
favor of apoptosis. This first event triggers the caspases
cascade activation, followed by poly-ADP-Ribose polymerase
(PARP) cleavage and chromatin fragmentation. Inactivation
of p53, by using Small Interfering RNA, renders LnCap cells
more resistant to EGCG-mediated apoptosis. On the other
hand, stable transfection of PC3 cells (that are endowed
with a mutated and inactivated p53 protein) with a cDNA
encoding wild-type p53, allows to by-pass their resistance
to EGCG-mediated apoptosis [24]. Ablation of p21 or Bax
confers a growth advantage to the cells through inhibi-
tion of the mitochondrial pathway of caspase-dependent
apoptosis.
Tumour necrosis factor-related apoptosis-inducing lig-
and/Apo2L ligand (TRAIL/Apo2L) is believed a promising
candidate for cancer therapy, even if emergence of drug
resistance limiting its potential use occurs.
Siddiqui et al. [25] reported that EGCG treatment sensi-
tizes TRAIL-resistant LNCaP cells to TRAIL-mediated apop-
tosis through modulation of apoptotic pathways. TRAIL/
Apo2L, when combined with EGCG, exhibited enhanced
cells apoptotic activity, characterized by three major molecu-
lar events: (i) increase of PARP cleavage; (ii) proantiapoptotic
Bcl2 family proteins modulation, favoring apoptosis; (iii)
synergistic inhibition of apoptosis inhibitors and concomi-
tant increase in caspase activation.
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2.3. Anti- or Pro-Oxidant Eﬀects and Activation of Phase II
Detossifying Enzymes. GTCs were shown to suppress cell
growth and induce apoptosis in DU145, through increasing
ROS formation and mitochondrial depolarization. Although
the molecular mechanisms are still not clear, GTCs-induced
apoptosis is not related to the members of Bcl2 family, as
EGCG did not alter Bcl2, BclX(L) and BAD expression, in
this cell line [26].
Nuclear factor-E2-related factor 2 (Nrf2) is a transcrip-
tion factor that plays a pivotal role in the antioxidant
response and oxidative stress, through activation of phase II
detoxifying or antioxidant enzymes [27, 28]. EGCG, as well
as other electrophile natural compounds, are able to activate
a core antioxidant responsive element (EpRe), present in
the promoter region of many genes involved in the cellular
response to oxidative stress [28, 29]. A widely acceptedmodel
for induction of EpRe-mediated antioxidant gene expression,
plausible also for EGCG, involves phosphorylation of Nrf2,
leading to enhanced Nrf2 accumulation and subsequent
EpRe binding [28].
Activator Protein-1 (AP-1) is a redox-sensitive transcrip-
tion factor that transduces modifications of the cellular redox
status, modulating the expression of genes, including pro-
survival genes, in responses to oxidative and electrophilic
stresses.
Nair et al. [30] demonstrated that EGCG, when admin-
istered to PC3 cells together with sulforaphane (SFN) is able
to reduce AP-1 induction. The authors also confirmed, by
“in silico” analyses, the presence of conserved transcription
factor binding site in the Nrf2 and AP-1 promoter region,
suggesting that gene expression changes induced by SFN and
EGCG, could be mediated via concerted modulation of the
Nrf2 and AP-1 pathways [30].
2.4. Modulation of the NFκB Signalling and Inhibition of
Inflammation Pathways. NFκB is a redox sensitive transcrip-
tion factor, often overexpressed in tumor and cancer cell
lines, that has been suggested to regulate a variety of cel-
lular functions, including inflammation, immune response,
growth, and cell death. NFκB resides in the cytoplasm, bound
to its inhibitor IκB; once the inhibitor is released, NFκB
phosphorylation occurs, followed by its translocation to the
nucleus.
EGCG has been shown to decrease the DNA binding
activity of NFκB, and reduce the expression of the p65 sub-
unit of NFκB in LNCaP cells, stimulated by tumour necrosis
factor alfa. NFκB over-expression is an important target in
PCa due to the regulation of various downstream targets that
include the cylcooxygenase-2 proteins (COX-2) [23].
In the LNCaP (androgen-dependent) and PC3 (andro-
gen independent) prostate cancer cells, EGCG was shown
to inhibit mitogen stimulated COX-2 expression through a
mechanism probably involving the regulation of transcrip-
tion factors, like NFκB, and not the direct binding to the
enzyme [31]. Moreover, LnCaP and PC3 cells treatment with
a combination of EGCG and COX-2 inhibitors resulted in:
(i) enhanced cell growth inhibition; (ii) caspase-dependent
induction of apoptosis and PARP cleavage; (iii) inhibition
of peroxisome proliferator-activated receptor gamma; (iv)
NFκB inhibition, when compared with the eﬀects of the
two singularly employed agents, suggesting that they play a
synergistic role [32].
Matrix metalloproteinases (MMPs), generally involved
in extracellular matrix degradation, result overexpressed in
PCa and play an important role in tumor progression and
invasion. NFκB is the key transcription factor involved in the
regulation of MMPs genes.
In DU145 cells Vayalil and Katiyar [33] demonstrated
that EGCG inhibits MMP-2 and MMP-9 (inactive and active
form expression) through a dose-dependent phosphoryla-
tion inhibition of the extracellular signal-regulated kinase
(ERK1/2) and p38 pathways. Inhibition of the activation of
transcription factors c-jun and NFκB also occurs.
Siddiqui et al. [25] observed that EGCG, administered in
combination with TRAIL, can inhibit LNCaP cells invasion
and migration potential. The authors found the eﬀect is
mediated through inhibition of the expression of the fol-
lowing factors: vascular endothelial growth factor (VEGF),
urokinase plasminogen activator (uPA), and angiopoietin
1 and 2. A significant inhibition in both MMP-2 and -9
protein expression and activity occurs, in the presence of up-
regulation of the tissue inhibitor of metalloproteinases 1.
2.5. Insulin-Like Growth Factor (IGF) Axis, Mitogen-Activated
Protein (MAP) Kinases Pathway, Phosphoinositide-3 Kinase
(PI3K/AKT) Pathway. It has been suggested that the IGF axis
plays a relevant role in PCa onset and development. Binding
of IGF1 to its cognate receptor activates the intracellular
tyrosine kynase domain, that produces phosphorylation of
many protein substrates, including members of the MAP
kinase cascade and PI3K/AKT. MAP kinases and the PI3K/
AKT pathway are both involved in the complex modulation
of signalling pathways, which regulates cellular processes like
proliferation, survival/death, and motility, usually altered in
carcinogenesis.
It has been reported that EGCG inhibits IGF-1 receptor
activity with an IC50 of 14 μM [34]. Treatment of DU145 and
LNCap cells with subapoptotic EGCG doses reduces IGF-
induced growth [35].
Siddiqui et al. [36] found that EGCG is able to: (i)
decrease PI3K and phospho-Akt levels and (ii) increase
ERK1/2 level in both DU145 and LNCaP cells. Treatment
of PC3 cells with EGCG results in activation of the ERK1/2
pathway, that is, not dependent by mitogen-extracellular
signal-regulated kinase (MEK), the immediate upstream kin-
ase responsible for ERK1/2 activation, suggesting an MEK-
independent signalling mechanism. Pretreatment of PC3
cells with a PI3K inhibitor partially reduced both EGCG-
induced ERK1/2 phosphorylation and cell proliferation
inhibition. These results suggest that ERK1/2 activation via a
MEK-independent and PI3-K-dependent signalling pathway
is partially responsible for the antiproliferative EGCG eﬀects
in PC3 cells [20].
2.6. Androgen Receptor (AR) and Prostate-Specific Antigen
(PSA). Experimental evidences suggest that androgens are
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involved in PCa development and progression, being AR
the essential mediator for androgen action. Detailed mech-
anisms of AR activation and modified function in PCa are
reviewed in [37–39]. Briefly, the AR is a nuclear receptor
activated through binding of its cognate ligands, such as
testosterone and 5alfa-dihydrotestosterone, and consequent
dissociation by the heat shock proteins (normally bounded
to it in the resting state). The activation process involves
several coactivators recruitments. Activated AR up regulates
the transcription of genes containing androgen response
elements in their promoters as PSA gene that, specifically
expressed in prostate, has been widely utilized for PCa
screening, in the last 20 years [40]. A very recent report by
means of a fluorescence resonance energy transfer (FRET)
based assay provides evidence that EGCG is a direct antago-
nist of androgen action.
EGCG is capable to physically interact with the ligand-
binding domain of AR by replacing a high-aﬃnity-labeled
ligand (IC50: 0.4 μM) [41].
In diﬀerent LNCaP sublines, EGCG suppresses cell pro-
liferation, PSA expression, and AR transcriptional activity,
at concentration comprised in the 10–20 μM range [42, 43].
The eﬀect on PSA expression might be related to reduction
of AR activity, but it should also be considered, that
EGCG, in vitro, can down regulate PSA by direct action on
transcription and translation mechanisms [44, 45].
3. PCa Chemoprevention by Green Tea
Polyphenols in Transgenic Mouse Model
Progress toward understanding the PCa biology has been
slow due to the few animal research models of tumour onset
and progression, available to study the spectrum of this
uniquely human disease. Genetically engineered mice are
being increasingly employed for delineating the molecular
mechanisms of PCa development and the potential of new
compounds as chemotherapeutic/chemopreventive drugs
against it. Animalmodels present a rapid tumor growth com-
paring to the long latency of human PCa, which, on the other
hand, makes the disease an ideal target for chemoprevention
strategies. Mouse dorsolateral prostate lobe is functionally
equivalent to human prostate peripheral zone, from where
the majority of human cancer originate [46]. Preclinical
studies with GTCs or with pure EGCG, administered at
a human achievable doses, have been conducted in both
transgenic animals and xenograft tumor models, in which
murine and human cell lines, derived from primary tumor
or metastasis, have been implanted subcutaneously [47, 48]
or injected intraprostatically [49].
To the aim of studying human CaP, autochthonous
murine models appear more suitable than orthotopic cell
lines transplantation. In fact, transgenic mice exhibit sets
of interactions between the diﬀerent cellular, tissue and
hormonal compartments appropriate to human prostate.
Among the several lines of transgenicmice generatedmodels,
the transgenic adenocarcinoma of mouse prostate (TRAMP)
has been well characterized and employed for a number
of pre-clinical trials. Mice expressing the transgene display
progressive forms of prostatic disease that histologically
resemble human PCa, from mild intraepithelial neoplasia
(PIN) to poor diﬀerentiate adenocarcinoma phase (PD) and
finally to metastatic spread [50]. In the TRAMP model, the
SV40 early genes (T and t antigens, Tag) are under the
control of the minimal rat Probasin promoter −426/+28—
fragment [50], which renders the transgene expression
androgen dependent, restricting it to the epithelial cells of the
dorsolateral and ventral prostate lobes, thus abrogating p53
and Rb function [51] and inactivating protein phosphatase
2A (PP2A), specifically in this tissue [52].
In many experimental studies conducted by Gupta et al.
[53] and by other authors [54–57], TRAMP mice aged from
8 to 32 weeks, received 0.1% oral infusion of a 95% GTCs
enriched mixture. The animals, when compared to water-
fed TRAMP mice, presented a significant delay in primary
tumor incidence and almost complete metastases inhibition;
prostate and genitourinary tract weight, a well-known tumor
growth index, was decreased (64% and 72%, resp.), correlat-
ing with the reduced expression of Proliferating Cell Nuclear
Antigen (PCNA).
The insulin-like growth factor pathway IGF/IGFBP-3 has
been suggested to regulate PCa growth and development
through its gradually increased activation during cancer
progression.
After GTCs administration TRAMP mice showed a
significant decrease in the IGF/IGFBP-3 ratio [54], accom-
panied by an inhibition of the downstream signaling cascade
that involves both PI3K/AKT and MAPK pathways. Also,
a parallel inhibition of vascular endothelial growth factor
(VEGF), matrix metalloproteinases MMP-2, and MMP-9
expression were demonstrated [55]. Furthermore, the au-
thors showed that metastasis-promoting Mts1 (S100A4)
level, that, as a rule increases in cancer development, resulted
in markedly decreased, E-cadherin level, that is progressively
lost during cancer progression, where restored [56]. Also, the
NFκB pathway activity, generally activated as a function of
tumor grade, was reduced after 32 weeks of EGCG treatment,
at a time when a shift in balance between Bax and Bcl2,
favoring apoptosis, also occurred [57].
Under similar experimental conditions, we observed
that, while 100% of TRAMP mice underwent PCa at 24
weeks of age, exhibiting tumor cell transendothelial passage
in the absorbing lymphatic vessels, only 20% of the animals
receiving 0.3% of GTCs (oral infusion), developed the
neoplasm [19, 58–60]. In TRAMP mice presenting tumor
growth arrest, a sequence of events were demonstrated, such
as downregulation of H3 histone (a process usually aﬀecting
chromatin structure and gene expression), upregulation of
growth arrest-Specific gene 1 (GAS1) and suppression of
Mini-Chromosome Maintenance protein 7 (MCM7), a
marker of DNA synthesis, essential for its replication, that
is aberrantly expressed in various cancer types.
Interestingly, the level of the secretory protein clusterin
(CLU) and mRNA, dramatically downregulated with the
disease onset and development, resulted to accumulate
progressively in the prostate after GTCs administration and
remain undetectable in the 20% of animals that presented
PCa, in spite of receiving GTCs solution. In correlation with
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these observations, when tumor progression was inhibited,
organelles committed to protein synthetic and secretory
activities, as endoplasmic reticulum and Golgi apparatus,
appeared significantly reduced in the prostate, suggesting
possibly protein posttranslational processes alterations [60].
We suggest that CLU might participate in the chemopreven-
tive action exerted by GTCs in TRAMP mice [19].
Harper et al. [61], after treating a cohort of TRAMP
mice with almost pure 0.06% EGCG in drinking water,
demonstrated that the compound can act only by slowing
PCa progression. EGCG inhibited early (12-week-old mice),
but not late (28-week-old mice) PCa stage. The treat-
ment resulted in many various eﬀects: AR, IGF1, and its
receptor decreased level, apoptosis-reduced cell prolifer-
ation, and phospho-extracellular signal-regulated kinases
1/2, cyclooxygenase-2, and inducible nitric oxide synthase
reduced activities. To a better interpretation of the data, it is
worthwhile noting that green tea polyphenols bioavailability
and transformation are key factors that can limit the com-
pound activities in vivo; EGCG, as a single agent, may present
a low bioavailability and/or slow its rapid metabolism,
when stabilized by the naturally occurring mixture of green
polyphenols. In addition, attention has to be paid when
comparing experimental works on TRAMP mice colonies
obtained through diﬀerent background strains. In fact, the
genetic background may have a profound eﬀect on some
aspects of tumor initiation/progression in this animal model.
The latest experimental work from Adhami et al. [62]
confirmed the eﬃcacy of 0.1% GTCs in drinking water to
TRAMP mice, starting at defined stages of PCa onset and
progression: 6 weeks (normal prostate), 12 weeks (PIN), 18
weeks (well-diﬀerentiated adenocarcinoma, WD), 28 weeks
(poorly-diﬀerentiated adenocarcinoma, PD), finally cancer
development. Tumor-free survival was indeed extended to
38 weeks in the 6 weeks group mice, but only to 24 weeks
in the 18 weeks group, compared with 19 weeks in water-fed
controls. Additionally, IGF and its downstream targets were
significantly inhibited only when intervention was initiated
at early stages.
The study design was conceived as a response to the
outcomes of human clinical trials, based on alternative and
complimentary green tea therapy, showing minimal eﬀect on
hormone-refractory PCa stage (CRPC) [63, 64], but lower
incidence on high grade PIN stage [65, 66].
Extensive laboratory studies in multiple animal models
consistently show the GTCs inhibitory activities against
prostate carcinogenesis [14] and suggest the importance of
identifying the most vulnerable PCa stages towards GTCs
chemoprevention in humans.
4. Possible PCa Chemoprevention by
Green Tea Polyphenols in Humans
4.1. PCa: Statistics and Importance for Chemoprevention
Strategies. PCa is the second most common cancer in Amer-
ican men with a 1 in 6 lifetime risk of developing it. The
National Cancer Institute (NCI) estimated that approxi-
mately 217,730 new cases PCa would have been diagnosed
in 2010 and there would have been approximately 32,050
PCa deaths [67]. In Europe, PCa has become the most
common non-skin cancer neoplasm among men, with an
estimated 382,000 cases occurred in 2008 [68]. Incidence has
increased rapidly over the past two decades, and rates are
dramatically influenced by PSA testing, as well as by latent
cancer detection in prostate surgery.
According to a recent report from the prostate, lung,
colorectal, and ovarian cancer screening trial, six annual
PCa screening programs (10 years followup results) led to
increased number of diagnosed cancers, in the screening
cohorts, but no cancer-specific survival advantage was seen
for the group. Therefore, the real possibility to “overdiag-
nose” and “over-treat” cancers which are not life threatening,
must be carefully taken in account [69]. A reasonable
explanation for the low eﬃcacy of invasive radical inter-
vention, which are the gold standard in clinical practice
after a diagnosis of confined PCa, relies on the fact that the
disease is biologically heterogeneous and its natural history is
almost unpredictable. Some cancers growth slowly, showing
indolent course, while others are very aggressive, quickly
progressing to advanced metastatic stage, that is almost an
incurable disease [70]. Therefore, it is important and urgent
to search for prevention strategy, eﬀective when the disease
is still at an early and potentially curable stage. PCa is
an ideal candidate for chemoprevention, because it has a
high prevalence, a long latency, and it is potentially lethal.
Preventive strategies could carry a high economic benefit
on the healthcare system reducing the costs associated with
PCa diagnosis and therapy, moreover, it might have a deep
positive impact on the patients quality of life, reducing the
morbidity associated with radical surgery (incontinence and
impotence) [71].
4.2. Epidemiological Evidence of Green Tea Eﬃcacy in PCa
Chemoprevention. PCa etiology is multifactorial, but the
marked disparity in its incidence between “Eastern” and
“Western” cultures suggests that dietary and lifestyle factors
play an important role in the disease development and
progression. This is strongly supported by migratory studies
showing that Asian men, who relocate to the United States
of America and adopt a western lifestyle, have a significantly
higher PCa risk, when compared to their native Asian
counterparts [72, 73].
During the last two decades, the relationship between
tea consumption and cancer has been a subject of research
interest for many investigators. Unfortunately at present,
many epidemiological studies present conflicting results
about the green tea role in cancer prevention. Recently, an
exploratory meta-analysis of observational studies supported
the hypothesis that green, but not black tea, may have a
protective eﬀect against PCa. A total of six epidemiological
studies, including two case-control studies as well as four
cohort studies, evaluated green tea role in reducing devel-
oping PCa risk [74–79]. A borderline statistical significant
decrease in the disease development is presented with
increasing green tea intake and, moreover, only case-control
studies (odds ratio, OR= 0.43; 95% CI: 0.25–0.73), but not
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prospective cohort studies (OR= 1.00; 95% CI: 0.66–1.53)
reached a statistically significant result [80].
Negative and conflicting results in epidemiological data
may be due to study design pitfalls and to many hardly
controllable variables, like tea infusion composition and way
of preparation (temperature), GTCs bioavailability, diet and
the lifestyle of the people included in the study, and last
but not least, genetic diﬀerences in the ability to metabolize
GTCs.
4.3. Pharmacokinetic Studies, Phase I Clinical Study, GTCs
Metabolism and Tissue Distribution. Polyphenon E is a
GTCs-enriched and defined product, virtually caﬀeine free
(<0,5%) produced by Mitsui Norin Co. Ltd, a new drug
investigated by the Food and Drug Administration. It con-
tains 80% to 98% total catechins by weight, with EGCGmain
component, accounting for 50% to 75% of the material.
Chow et al. [81, 82] performed several pharmacokinetic
phase I studies (in healthy volunteers) utilizing Polyphenon
E (capsules) to determine the systemic tea polyphenols
availability after a single or multiple dose and various dosing
condition (200, 400, 600, 800mg of EGCG). In the single-
dose study, Polyphenon E was compared to pure EGCG
for diﬀerences in pharmacokinetic parameters [81]; after its
administration, at the four dose levels above mentioned,
the average EGCG peak plasma concentration (Cmax) was
72.7 ± 66.4, 125.3 ± 50.4, 165.7 ± 126.9, and 377.6 ±
149.8 ng/mL. Similar results were obtained after pure EGCG
administration, at the same concentration, suggesting that
GTCs and Polyphenon E do not have any eﬀect on the EGCG
pharmacokinetics. It should be noted that tea catechins
bioavailability is quite low in humans, resulting in plasma
concentrations 5 to 50 times less than concentrations shown
to exert biological activities in vitro [14].
In the multiple dose study, the same authors evaluated
eﬀects and safety following chronic Polyphenon E adminis-
tration [82], concluding GTCs do not accumulate in the body
and are safe for human health.
A third pharmacokinetic study from the same authors
[83], evaluated the role of fasted or fed state on Polyphenon E
bioavailability (400, 800, or 1200mg of EGCG), concluding
that Cmax of free catechins (EGCG, EGC, EC) can be
increased of about 3-folds, when administered in a fasted
state. The first study demonstrating that GTCs can be
detected in the prostate tissue after green tea consumption
has shown that after a short period (5 days) of green tea
continuous intake (1.42 L of brewed tea divided in 5 daily
doses), the prostate GTCs concentration were 0.1, 0.043,
0.040, 0.0021 (nmol/g tissue) for EGC, EC, EGCG, and ECG,
respectively [84].
4.4. Proof of Principles and Phase II Studies of Green Tea
Eﬃcacy for PCa Chemoprevention and Treatment. There have
been 5 intervention studies evaluating the GTCs eﬀect on
PCa treatment or prevention [63–65, 85, 86]. Three were
single-arm open-label phase II trials, performed in patients
diagnosed with a castration resistant PCa (CRPC) [63, 64,
86] and one was a pilot proof of concept study, performed
to evaluate GTCs ability to reduce cancer incidence in a
well-defined cohort of patients, bearing premalignant lesions
(HGPIN) [65].
The most recent study, a randomized, double-blind,
placebo-controlled phase II trial evaluated the eﬀect of
short-term Polyphenon E administration in men with PCa
scheduled to undergo radical prostatectomy [85].
The primary endpoint of the trial reported in [64] was to
determine the capacity of nonstandardized green tea powder
to produce a PSA base level decline in 42 men with clinical
CRPC evidence. Only 1 patient, among 42, manifested a
transitory 50% decreased PSA level from baseline, during
the 6 months followup. The negative result of this study
needs to be critically considered; it should be taken into
account that the enrolled population comprised men with an
advanced cancer stage, that acquired resistance to standard
hormone deprivation therapy, and that a nonstandardized
GTCs preparation was employed.
Choan et al. [63] published the results of a study aimed to
evaluate the eﬀect of a standardized green tea extract (250mg
GTCs/day) on PSA level or measurable marks of the disease
progression, after a minimum of 2 months therapy. Only 15,
out of the enrolled 19 patients, completed at least 2 months
therapy and all of them exhibited a progressive disease in
the first 4 months. In addition, a very small population
with an advanced cancer stage, unresponsive to previously
administered hormonal therapy, was considered.
On the basis of encouraging results obtained by us and
others in the PCa chemoprevention with animal models
[19, 53, 62], our research group performed a proof of concept
trial in a well-selected patients cohort at high risk to develop
PCa [65]. We enrolled 60 patients with HGPIN diagnosis,
that were randomly assigned to receive, according to a
double-blind procedure, a standardized GTCs formulation
(600mg/day), or identical placebo capsules for 1 year. GTCs
composition, virtually caﬀeine free, was total catechins
75.7%; EGC, 5.5%; EC, 12.2%; EGCG, 51.9%; ECG. All the
patients, during the study, were subjected to regular prostate
biopsy (6 and 12 months after the study beginning) to asses
diﬀerences in PCa values between the two arms. Total serum
PSA concentration was measured at 3, 6, 9, and 12 months,
to check whether GTCs administration would reduce the
value. Because concomitant benign prostate hypertrophy
(BPH) was very common among the patients enrolled, we
also evaluated the International prostate symptom score
(IPSS) and quality of life (QoL) after 3 months of GTCs
administration in a subcohort of patients with low urinary
tract symptoms (LUTSs), as a further secondary end point.
We found that 9 out of 30 patients receiving placebo
developed PCa, while only 1 out of 30 patients receiving
GTCs was found PCa positive after prostate biopsy. We did
not find any significant diﬀerence in PSA values between
the 2 arms, but we found a significant IPSS and QoL scores
improvement.
Our results point the attention on the fact that GTCs
should be considered interesting and promising natural
compounds for PCa chemoprevention, while they are almost
ineﬀective in case of full-developed metastatic neoplasia
(CRPC). We also found that PCa incidence remained low
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in patients belonging to the GTCs-arm, even two years
after therapy suspension [66]. This result may suggest that
chemoprevention activity and clinical benefits achieved with
GTCs are stable over time. We hope that our data will be
confermed by a large phase II study, now ongoing, sponsored
by NCI. This trial is aimed to enroll about 300 HGPIN
patients to be given 400mg/day of Polyphenon E for PCa
prevention. (Study of Polyphenon E in men with high-
grade prostatic intraepithelial neoplasia, Protocol IDs: MCC-
15008, R01 CA12060-01A1, NCT00596011).
McLarty et al. [86] published the results of a study aimed
to evaluate the eﬀect of short term (median treatment period
34.5 days) GTCs administration in a population of PCa
diagnosed patients, scheduled for radical prostatectomy. The
supplementation, performed with an high, well-tolerated,
Polyphenon E dose (1.3 g GTCs/day) produced a significant
decrease of biomarkers relevant for PCa development, like
HGF (hepatocyte growth factor), VEGF (vascular endothelial
growth factor), IGF-1 (insulin growth factor-1) and IGFBP-
3 (insulin growth factor binding protein-3). These results
support a potential GTCs role in PCa chemoprevention and
treatment in early confined stage.
Disappointingly, the positive Polyphenon E influence
resulted not statistically significative according to the results
of a randomized, double-blind, placebo-controlled trial,
having a study design strictly close to that of McLarty [85].
The reason(s) for the discrepancy between the two studies
remains to be elucidated, but it should be considered that the
lack of a control group in the single arm study made it easier
to gain statistical significance. On the other hand, it may
indicate that future studies would need a larger population
to show a statistically significant diﬀerence in systemic
biomarkers and Polyphenon E, or generally standardized
GTCs formulation, should be preferentially tested in longer-
term intervention studies and in a precancerous model,
where its eﬀects have a best chance to be demonstrated.
5. Molecular Mechanisms for Green Tea
Polyphenols Anticancer Activity in
PCa: An Emerging Role for Epigenetics
5.1. Modulation of Epigenetic Mechanisms. In the last five
years, GTCs have been shown to be able to modulate all the
principal epigenetic mechanisms: DNA methylation, regu-
lation of chromatin structure (through histone posttransla-
tional modifications), and alterations of noncodingmiRNAs.
Epigenetics is defined as changes in gene expression that do
not involve changes in the DNA sequence. Importantly, these
changes are both reversible and heritable through division of
somatic cells, making epigenetic regulation of gene expres-
sion a dynamic process that plays a crucial role in a vast
number of biological processes including development, cell
diﬀerentiation, stem cell maintenance, and tissue homeosta-
sis [87]. Deregulation of epigenetic mechanisms is found in
numerous diseases and in virtually every kind of cancer. This
observation, together with the dynamicity, and therefore the
potential reversibility, of epigenetic mechanisms sparked the
interest in developing epigenetic drugs capable to modulate
DNA methylation and chromatin structure in cancer cells.
In the last few decades, several epigenetic drugs have been
developed and are now either tested in clinical trials or
already established in the clinical care, even if the drugs,
besides modulating epigenetic mechanisms, appear to exert
a certain degree of cytotoxicity.
The observation that GTCs, together with other dietary
polyphenols, can regulate specific epigenetic features of
premalignant and malignant cells opens new possibilities for
epigenetic therapy
5.2. DNA Methylation. DNA methylation is an important
epigenetic determinant in gene expression. As a matter of
fact, it participates in the maintenance of DNA integrity and
stability, in chromosomal modification, and development of
mutations. Generally, DNA hypermethylation is associated
with genes inactivation and global genomic hypomethylation
is associated to chromosomal instability induction. The DNA
methylation occuring on the carbon-5 position of cytosine
residues within a CpG dinucleotide sequence, represents
the most studied epigenetic marker. In normal tissues, the
process shows a bivalent function: CpG sites clustered in
regulatory regions, within promoters and enhancers (CpG
islands), are usually unmethylated, allowing for genes to be
expressed; while sparse CpG sites (throughout the genome)
are usually methylated, contributing to genome stability
[88]. DNA methylation is crucially dysregulated in the vast
majority of cancers, where CpG islands become hyperme-
thylated, causing silencing of many genes, involved in cell
cycle regulation, tumor suppression, DNA repair enzymes,
receptors activity, and apoptosis, while the sparse CpG sites
are usually subject to hypomethylation, favoring genomic
instability, a common feature of cancer etiology [89].
Epigenetic analysis oﬀers a potential noninvasive blood
marker, complementary to PSA, for a preliminary PCa diag-
nosis. Since inhibition of DNA methyltransferases (DNMTs)
may prevent hypermethylation and silencing of tumor
suppressor key genes, it is reasonable to suppose that
enzyme inhibition, along with histone deacetylase activation,
may contribute to cancer treatment and or carcinogenesis
prevention.
In human prostate cancer PC3 cells, as well as in other
cell lines, Fang et al. [90] demonstrated that EGCG decreases
total DNMTs activity, leading to reactivation of several genes
silenced by methylation, such as retinoic acid receptor beta
(RARb), which expression results increased by lowering
the methylation levels of its promoter. This is the first
demonstration of such an activity of a commonly consumed
dietary constituent.
Recently, it has been reported that exposure of human
prostate cancer LnCaP cells to GTCs causes a time-and
concentration-dependent reactivation of the expression of
the gluthathione-S-transferase p1 gene (GSTP1) [91]. The
gene, mostly studied for methylation in PCa, results hyper-
methylated in almost 90% of the tumors [92]; in fact, it is rec-
ognized as a molecular PCa hallmark. Cells treatment with
GTCs results in GSTP1 promoter demethylation, associated
with a significant reduction of DNMT1 activity. Interestingly,
the treatment does not cause global sparse CpG sites
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hypomethylation, contributing to maintain genome stability.
The authors present GTCs as excellent candidates for epi-
genetic chemoprevention against PCa, even more favorable
than the most commonly DNMT inhibitors employed, such
as 5-aza-2′deoxycitidine.
There is growing evidence that the epigenetic mecha-
nisms that impact DNA methylation and histone status, also
contribute to genomic instability. Instead, GTCs adminis-
tration lacks of toxicity, do not reactivate the prometastatic
gene S100P, as a reverse response of 5-aza-2′deoxycitidine
administration, and is able to alter chromatin modeling by
histone acetylation (the second global epigenetic mechanism
of gene regulation, see below) [91].
Almost at the same time, Morey Kinney et al. [93]
showed that GTCs administration to TRAMP mice (sponta-
neously developing prostate adenocarcinoma) had very little
eﬀect on DNA methylation. They have found that 5-methyl-
deoxycitosine level, together with methylation levels of B1
repetitive elements and the Mage-a8 gene, that are correlated
to the phenomenon, remained unchanged in wild-type and
TRAMP mice prostate. Also, they performed a genome-
wide DNA methylation profiling of the HpaII tiny fragment
enrichment by ligation-mediated PCR (HELP) [94] and
found no significant hypomethylation. Their study, however,
arises some doubts on the interpretation of the data: most
of the analysis is directed towards sparse CpG site, rather
than CpG islands. Indeed, the lack of global hypomethylation
in GTCs fed mice agree with the above results obtained
in LnCaP cells [91]. Second, but most important, in their
study, GTCs treatment did not cause chemopreventive eﬀects
on PCa development, in contrast with previous reports by
other authors [19, 53]. The diﬀerent composition of the
GTCs preparation used by Morey Kinney et al. [93] might
account for this discrepancy, since it contained only about
half of the ECGC concentration (35%) relative to the other
polyphenols, when compared to the preparations used in
other studies (51.9% in [19] and 62% in [53]).
Among the still growing number of experiments aimed
to clarify the GTCs power as epigenetic drugs against PCa,
there is plenty of evidence that the GTCs can interfere
with DNA methylation pathways in vitro, leading, also, to
the reactivation of the tumor suppressor p16, known to be
involved in the cell cycle regulation [95].
Three diﬀerent molecular mechanisms, at least, have
been proposed to explain GTCs eﬀects on the DNA
methylation process (Figure 2). In human models, GTCs
are demonstrated to be readily methylated, by catechol-
O-methyltransferase (COMT) which utilizes S-Adenosyl-L-
methionine (SAM) as a methyl donor, producing equimo-
lar concentration of S-adenosyl-L-homocysteine (SAH). It
should be noted that SAM is an indispensable methyl donor
for DNMTs and SAH is a potent inhibitor of DNMTs activity.
Since GTCs administration causes both decreased SAM and
increased SAH cellular concentrations, the hypothesis is
proposed that GTCs may act by perturbing the regulatory
physiological homeostasis of the two molecules [96].
This mechanistic explanation is supported by Lee
et al. [97]. The authors, utilizing multiple modelling tools,
have shown that the inhibitory eﬀect exerted by several
polyphenols on human DNMT1 is increased after in vitro
COMT addition. In these experiments, EGCG resulted the
much more potent DNMT1 inhibitor, able to act also
independently of the COMT presence. In addition to the
indirect action on DNA methylation demonstrated by [96],
EGCG is able to inhibit DNMT1 by directly binding to the
enzyme [90], with the gallic acid moiety of the molecule
playing a crucial role in the interaction (Figure 2).
In human cell lines, EGCG is shown to act as an
antifolate compound and disturb the folic acid metabolism
by inhibiting dihydrofolate reductase. Since folic acid physi-
ologically modulates DNA methylation, Navarro-Peran et al.
[95] hypothesize that many molecular eﬀects imparted by
EGCG administration might be explained by this kind of
interference with DNA methylation (Figure 2).
5.3. Chromatin Structure. Changes in the chromatin con-
densation, a crucial mechanism to control gene expression
in eukaryotic cells [98], is regulated by at least eight
posttranslational modifications of histones, such as acetyla-
tion, methylation, phosphorylation, poly-ADP-ribosylation,
ubiquitination, glycosylation, and so forth, predominantly
occurring on lysine residues [99]. Combinations of the
diﬀerent modifications constitute the histone code that
defines the actual or potential transcriptional state [100]
through proteins-DNA interaction, which in turns regulates
gene expression.
Among the most studied processes, histone acetyla-
tion/deacetylation is finely regulated by balancing the activ-
ity of acetyl-transferases (HATs) and histone deacetylases
(HDACs) enzyme families; inhibition of the latter rapidly
results in histone hyperacetylation. Acetyl groups added to
lysine residues by HATs, mainly on H3 and H4 histones, neu-
tralizes aminoacid positive charge and consequently loosens
DNA binding to histone complexes, ultimately resulting in
chromatin relaxation and gene activation [99].
Being HDACs overexpression implicated in protecting
cancer cells from genotoxic insults, many HDAC inhibitors
synthesized in order to favor tumor suppressor genes re-
expression and silence DNA repair pathways, are gaining a
momentum as a novel cancer therapy. Raiendran et al. [101],
however, indicate how dietary phytochemicals, by aﬀecting
the epigenome, and also can trigger DNA damage and repair
mechanisms.
With regard to PCa, Pandey et al. [91] have observed a
time-dependent inhibition of the total HDACs activity, after
GTCs administration to LnCaP cells, correlating with mRNA
and HDAC1-2-3 classes decrease.
Recently, GTCs administration was shown to inhibit
HDAC1 activity and protein expression in PCa cell lines as
LnCaP (harboring wild-type p53) and p53-null PC3 (lacking
p53). When administered together a proteasome inhibitor,
GTCs eﬀect resulted prevented, indicating that HDAC1 is
proteasoma degradated. HDAC1 inhibition was followed by
up regulation of the cell cycle inhibitors WAF1/p21, ulti-
mately inducing G0/G1 phase cell cycle arrest and apoptosis
in both cell lines, irrespective of their p53 status [102].
A sustained DNA damage response, coupled with insuf-
ficient repair mechanisms, may be a pivotal mechanism
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Figure 2: Mechanisms of inhibition of DNMTs by GTCs. (a) In a cancer environment, specific genes are silenced by hypermethylation of
their promoters. DNA hypermethylation is catalysed by DNMTs, which use as a substrate SAM and release SAH as a by-product. (b) Within
this context GTCs are able to inhibit DNMTs through three distinct mechanisms. (1) Direct inhibition. (2) GTCs are methylated by COMT,
resulting in a depletion of SAM and accumulation of the DNMT inhibitor SAH. (3) Direct inhibition of DHFR, resulting in disruption of the
folate cycle that influences negatively the levels of SAM. Inhibition of DNMTs ultimately results in DNA hypomethylation and re-expression
of previously repressed genes.
for apoptosis induction in cancer cells exposed to dietary
phytochemicals. The above findings provide new insight
into the GTCs mechanisms, suggesting a novel approach to
prevention and/or therapy.
5.4. microRNAs. microRNAs (miRNAs) comprise a novel
class of endogenous, small, noncoding RNAs that control
gene expression by acting on target mRNAs for degradation
and/or translational repression. Transcription of miRNA
genes and protein-coding genes shares common regulatory
mechanisms: miRNA genes can be embedded in the introns
of protein coding genes or can derive from their own
transcript units in intergenic regions of the genome. When
miRNA genes are located within introns of protein-coding
genes, primary miRNA biogenesis is controlled by the
same transcriptional mechanisms as the parent gene. In
contrast, an independent miRNA gene will have its own
transcriptional controls. Interestingly, multiple miRNAs can
be produced within a single transcript, each of which can
act independently [103, 104]. The long primary nuclear
miR transcript (“pri-miRNA”) undergoes maturation by
the RNase-III Drosha/Dgcr8 enzyme complex, generating a
precursor miRNA (“pre-miRNA”) that is exported from the
nucleus by exportin-5 [105]. A second cleavage takes place in
the cytoplasm, involving the action of a complex containing
another RNAase III enzyme named Dicer [106], to generate
a single-strand mature miRNA. Mature miRNA, is usually
incorporated in RNA-Induced Silencing Complex, a complex
of proteins that is responsible for silencing the target mRNA
[107]. Translational inhibition or degradation of targeted
mRNA transcripts is due to imperfect or perfect base pairing
between positions 2 to 8 from the 5′miRNA (also known as
the seed sequence), with the 3′Un-Translated Region of their
target mRNAs [104].
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miRNAs are emerging as important regulators of gene
expression and we expect them to be key players in intra-
cellular signalling, thus enabling to close gaps of knowledge
in molecular pathways. Pathogenic roles of miRNAs were
initially described in cancer and miRNAs have now become
a hot topic in medical research [108].
5.5. microRNA in PCa. To our knowledge, by employing
miRNA microarray analysis, 7 miRNAs (miR-145, miR-141,
miR-125, miR-1, miR-133, miR-106b, and miR-16) have
been found downregulated in PCa [109–111]. In addition,
the chromosomal region containing the miR-15/16 cluster
and miR-101 is often lost during PCa progression. Table 1
summarizes recent publications on miRNAs in PCa.
Bonci et al. [112] demonstrated that reduced levels of
miR-15/16 are associated with PCa growth and due to an
increase in the protein levels of their target genes Bcl2,
cyclin D1, and WNT3A. Conversely, overexpression of miR-
15/16 suppresses tumor growth and induces its regression.
Expression of miR-101 inversely correlates with upregulation
of its target, enhancer of zezte homolog 2 (Ezh2), which is
highly expressed in CRPC [113].
miR-331-3p and miR-449a are downregulated in PCa,
contributing to cancer growth by overexpressing their tar-
gets ErbB2 [114] and HDAC1, respectively [115]. Poliseno
et al. [116] demonstrated that miR-22 and the miR-106b∼
25 cluster are overexpressed in PCa, and potentiate cellular
transformation both in vitro and in vivo. Intronic miR-
106b∼25 cluster cooperates with its host gene MCM7 in
cellular transformation both in vitro and in vivo.
Other tumor suppressor miRNAs in PCa are miR-34
expecially in p53-deficient PCa cells [117] and miR-330,
which suppresses E2F-1 and E2F-1-mediated AKT phos-
phorylation [118]. In PCa cells, miR-21 is induced by
stimulation of androgen receptors and mediates hormone-
dependent and -independent cell growth [119]; in contrast,
miR-221 increases in androgen-independent tumors [120].
MiR-146a, which is reduced in androgen-independent PCa
cells, inhibits proliferation and cell invasion by targeting of
RhO-activated protein Kinase 1 [121].
miRNAs that have been detected in human serum and
plasma specimens, and circulating miRNA profiles, have
now been associated with cancer, as an emerging class of
diagnostic and prognostic biomarkers. Specifically in PCa,
the expression of miR-141 has been found to be elevated
in the plasma of PCa patients [122], where levels of miR-
141 in PCa were able to predict tumor progression, when
compared with other validated prostate biomarkers [123].
Finally, miR-141, miR-298, and miR-375 were also found to
be upregulated at diﬀerential levels in the serum of men with
CPRC [124].
5.6. microRNAs in PCa and Polyphenols. Recently, studies
support a growing interest in the chemopreventive role
of dietary agents such as polyphenols, as modulators of
miRNA profiles in cancer progression and prevention [125];
(Table 2).
Table 1: miRNAs involved in PCa.
miRNAs Target genes References
miR-15/16 Bcl2, CCD1, WNT3a [112]
miR-101 Ezh2 [113]
miR-331-3p Erb2 [114]
miR-449a HDAC1 [115]
miR-146a ROCK1 [121]
miR-106b/25 PTEN [116]
miR-330 E2F1 [118]
Table 2: miRNAs modulated by polyphenols in PCa.
miRNAs Polyphenols Regulation References
miR-21 EGCG down [41]
miR-330 ECGC up [41]
miR-1296 Genistein up [129]
miR-17/92 Resveratrol down [130]
miR-106a/b Resveratrol down [130]
Although the chemopreventive eﬀects of EGCG, as well
as other polyphenols, have been largely demonstrated in PCa
by us [19, 59, 126] and other groups (reviewed in [127]),
only few reports discussed the regulatory eﬀect of miRNA
expression by dietary components in PCa. At the moment,
the first and only study that clearly correlated miRNA-
regulation with catechins treatment in PCa is performed by
Siddiqui et al. [41]. The authors studying the role of andro-
gen receptor (AR) in both early and advanced stage of PCa
etiology, showed that the androgen-regulatedmiRNA-21 and
the tumor suppressor miRNA-330, commonly regarded to
play a role in PCa, are, respectively, down- and upregulated in
a xenograft mice model for PCa, following EGCG treatment.
These findings strengthen EGCG as an androgen receptor
signalling antagonist, which can block AR gene expression
and cell growth in the human PCa cells. EGCG is suggested
as a chemotherapeutic agent against CPRC.
Basing on experiments performed in pancreatic cells with
the phytochemical substance curcumin by Bao et al. [128],
it appears worthwhile investigating the EGCG eﬀect on
miR-200 and miR-21 expression in PCa cells. Interestingly,
the increase of the two above miRNAs is correlated to
the induction of the critical tumor suppressor gene PTEN,
frequently defective in PCa.
A study examined the eﬀect of the phytochemical com-
pound genistein on minichromosome maintenance (MCM)
genes, commonly dysregulated in cancer, showing that
MCM2 expression genes is higher in PCa samples, whereas
miR-1296 was significantly downregulated [129]. Genistein
induced miR-1296 expression and subsequently downreg-
ulated the MCM2 expression, along with cell cycle arrest
in S-phase. This study is worth of our attention, since we
demonstrated a dramatic MCM7 genes suppression by GTCs
in the prostate of TRAMP mice [59]; analyses of therapeutic
eﬀect of catechins onmiR-1296 and onmiR-106b∼25 cluster,
request further investigations.
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Table 3: Principal progressive phases in human PCa development.
Definition Acronyms STAGE of PCa development STAGE where CTCs could be possibly used
Proliferative Inflammatory
Atrophy
PIA Precursor of cancer initiation YES
Prostatic Intraepithelial
Neoplasia
MILD PIN PreMalignancy YES
HIGH PIN Malignancy YES
Adenocarcinoma
WD Well-diﬀerentiated Cancer NO
PD POOR diﬀerentiated Cancer NO
Fully Developed Metastatic
Neoplasia
CRPC
Hormone refractory castration resistant
Terminal cancer
NO
Finally, utilizing miRNA microarrays, Dhar et al. [130]
found that miR-17-92 and miR-106ab clusters, with well-
recognized oncogenic properties, were significantly down-
regulated after treatment with the phytochemical compound
resveratrol.
To corroborate the hypothesis that EGCG may act as a
negative tumorigenesis process, downregulating oncogenes
miRNAs and/or upregulating tumor suppressor genes miR-
NAs, more definitive informations are needed.
6. Conclusion and Future Perspective
Despite the routinary employment of intermediate-risk
prognosticators such as PSA, Gleason score, and T-category,
PCa remains a complicate malignancy, exhibiting high het-
erogeneity features both when present in latent, clinically
indolent, and in progressively more aggressive stages, leading
to the “hormone refractory state” (CRPC). This is the most
devastating PCa form, representing the terminal stage of
transition from the androgen dependence stage, against
which, at the moment, no curative therapy exists.
Although radical prostatectomy is curative in the major-
ity of patients with clinically localized PCa, up to 40%
of them fail to respond to local therapy and develop PSA
recurrence, as a sign of metastatic growth; ultimately, many
of these patients die from their disease. While latent PCa
appears similarly frequent in men with diﬀerent ethnic back-
ground, residing in culturally diverse geographic locations,
experimental evidences show that the quality of diet and
lifestyle factors may carry the mechanisms triggering the
transition to the “hormone-refractory state” and, at the
same time, may be the target for the action of anticancer
prevention.
These considerations support the increasing use of com-
plementary and/or alternative therapies such as developing a
diet-based combinatorial approach. Chemopreventive action
of a naturally occurring, nontoxic agent, such as green tea
polyphenols, could be useful in the PCa management. Just
a postponement of the “hormone-refractory state” or the
maintenance of the androgen dependence would produce
chronic instead of terminal PCa. On the other hand, there
is growing consensus that a large subset of patients do not
require aggressive treatment. Recent preclinical evidences
showing that GTCs can inhibit cell cycle, induce apoptosis,
and modulate several signalling pathways, strengthened by
experiments with animal models, have demonstrated the
possible utilization of these compounds in selected human
PCa stages for preventing its development (Table 3).
To date, although additional investigations are needed,
a real cancer preventive activity by tea polyphenols has not
been consistently observed in the few studies with humans
versus the several studies with animal models so far achieved.
Table 4 suggests two main diﬀerences between humans and
animals studies: (1) relatively low quantities of GTCs intake
by patients, as compared to TRAMP mice (it is conceivable
that GTCs availability in the prostate is diﬀerent in mouse
than in humans; on the other hand pharmacokinetics studies
demonstrate EGCG limited systemic concentrations); (2)
various confounding factors (as genetic diﬀerences, diet,
lifestyle and, etc.) present during the patients treatment,
unlike the controlled conditions to which animals are
subjected to optimize cancer prevention eﬀect.
In the future, eﬀorts will be needed to monitor GTCs
administration to humans starting from the standardization
of optimal GTCs compositions and doses, and continuing
by enhancing GTCs bioavailability through nanocapsules
or liposome deliver (nanochemoprevention). Simultane-
ous check of plasmatic and bioptic EGCG levels will be
indispensable; it remains to be determined whether EGCG
undergo autooxidation in the prostate gland, as it occurs in
cell culture.
Certainly novel biomarkers focused not only on PCa
epithelial cells but also on cell interaction with the extracellu-
lar microenvironment, that will improve the ability to detect
PCa, predict lethality, and monitor response to therapies
(many markers validated in experimental studies are not yet
introduced as routine diagnostics).
Substantial information on tea polyphenols chemopre-
ventive activity will emerge from long-term and rigorous
clinical trials on well-designed cohorts of patients. Although
it may appear simplistic that clinical PCa heterogeneity is
attributable to underlying molecular heterogeneity, clinical
trials still have to consider the need of cohorts with definite
cancer risk, classified by their gene expression signature, that
represents a clinically relevant genetic biomarker, indepen-
dent of the current diagnostic variables. PCa develops via a
limited number of alternatively preferred genetic pathways,
providing genetic subtype (molecular classification) that
may constitute a framework for investigating PCa and
possibly explain the clinical heterogeneity of the disease with
regard to both tumor progression and therapeutic response.
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Table 4: Studies on the eﬀect of GTCs administration to TRAMP mice and humans with PCa.
Experimental groups
GTCs dose g/100mL
[oral administration]
Formulation (%)
PCa phases
age-dependent
(weeks)
PCa
inhibition
(%)
References
TRAMP mice
0.06
GTCsa
Start 5; end 12 83 [61]
EGCG (93)
0.1
GTCsb:
Start 8; end 32 42 [53]
EGCG (62)
ECG (24)
EGC (5)
EC (6)
0.1
GTCsb:
[62]
EGCG (62)
Start 6; end 38 ∼50
ECG (24)
EGC (5)
Start 18; end 24 ∼20
EC (6)
0.3
GTCsc:
Start 8; end 24 80 [19]
EGC (5.5),
EC (12.2)
EGCG (51.9)
ECG (6.1)
GTCs dose mg/day
[oral administration]
GTCs providers PCa phases
Percentage
(%) of PCa
inhibition
References
HUMANS
500 Sabinsa Corporation CRPC No eﬀect [63]
6000 Unilever CRPC No eﬀect [64]
1300
Polyphenon E Matsui
Norin,
CRPC Mild eﬀect [86]
600
Polyphenon E Matsui
Norin
HGPIN 33 [65]
800
Polyphenon E Matsui
Norin
CRPC No eﬀect [85]
GTCsa: Roche, GTCsb: natural resources and products, GTCsc: isolated by the investigators; CRPC (castration resistant prostate cancer), HGPIN (high grade
prostatic intraepithelial neoplasia).
Conclusively, to avoid diﬃculties in the interpretation
of the data, the future tea polyphenols protocols should
take into account the following: (1) standardization in the
preparation of the substances employed, choice of their doses
and concentrations, systematically tested in plasma as well in
biopsies; (2) more accurate stratification of a large number
of the patients utilized for the analysis and selection of an
appropriate treatment duration.
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